HomeToday’s HighlightsAmgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Amgen and UCB granted FDA approval of Evenity for osteoporosis in menopausal women at risk of bone fracture Today’s Highlights April 10, 2019 Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Amgen (AMGN), UCB Pharmaceuticals (UCB) April 10, 2019 Tweet Pin It Other Articles Reata Stock Holders Approved the Firm’s Merger with Biogen September 21, 2023 0 Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy September 18, 2023 0 Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia September 12, 2023 0 Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly September 11, 2023 0